Hyperpolarized 129Xe MRI of Survivors of COVID-19

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 22, 2021

Primary Completion Date

January 1, 2025

Study Completion Date

May 1, 2025

Conditions

Covid19

Interventions

DRUG

Hyperpolarized Xe129

Subjects will inhale up to 4 doses of hyperpolarized Xenon gas in order to image pulmonary function.

Trial Locations (1)

University of Kansas Medical Center, Kansas City

All Listed Sponsors

lead

University of Kansas Medical Center

OTHER

NCT04659707 - Hyperpolarized 129Xe MRI of Survivors of COVID-19 | Biotech Hunter | Biotech Hunter